Exhibit 99.1

omnicell_logo-hzxgrnxrgbxm.jpg

Contact:
Kathleen NemethOmnicell, Inc.
Vice President, Investor Relations590 East Middlefield Road
650-435-3318Mountain View, CA 94043
Kathleen.Nemeth@Omnicell.com

Omnicell Reports Fiscal Year and Fourth Quarter 2020 Results

Record 2020 Total Product Bookings of $1+ billion
Full Year 2020 Revenues of $892.2 million
Ended Year with 145 Long-Term, Sole-Source Agreements with the Top 300 U.S. Health Systems
Entered 2021 with Record Product Backlog of $924 million

MOUNTAIN VIEW, Calif. -- February 1, 2021 --
Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its fiscal year and fourth quarter ended December 31, 2020.
GAAP Results
Total revenues for the fourth quarter of 2020 were $249.2 million, up $0.9 million from the fourth quarter of 2019. Total revenues for the year ended December 31, 2020 were $892.2 million, down $4.8 million from the year ended December 31, 2019.
Fourth quarter 2020 GAAP net income was $16.4 million, or $0.37 per diluted share. This compares to GAAP net income of $22.1 million, or $0.51 per diluted share, for the fourth quarter of 2019.
GAAP net income for the year ended December 31, 2020 was $32.2 million, or $0.74 per diluted share. This compares to GAAP net income of $61.3 million, or $1.43 per diluted share, for the year ended December 31, 2019.
Non-GAAP Results
Non-GAAP net income for the fourth quarter of 2020 was $40.2 million, or $0.91 per diluted share. This compares to non-GAAP net income of $33.5 million, or $0.77 per diluted share, for the fourth quarter of 2019.
Non-GAAP net income for the year ended December 31, 2020 was $111.3 million, or $2.54 per diluted share. This compares to non-GAAP net income of $120.7 million, or $2.81 per diluted share, for the year ended December 31, 2019.
Non-GAAP net income for each period excludes, when applicable, the effect of share-based compensation expense, amortization expense of acquired intangible assets, acquisition-related expenses, restructuring and severance-related expenses, tax restructuring benefits and expenses, amortization of debt issuance costs, amortization of discount on convertible senior notes, and certain litigation costs.
Total product bookings for the year ended December 31, 2020 were $1.002 billion compared to $813 million for the year ended December 31, 2019, or an increase of 23% year-over-year. Total product backlog for the year ended December 31, 2020 was $924 million compared to $588 million for the year ended December 31, 2019, or an increase of 57% year-over-year.
“We had a strong fourth quarter and full year 2020, consistent with the preliminary results we announced last month. We are pleased to have exceeded our pre-pandemic bookings guidance and October 2020 guidance across all key metrics, including total revenues, total product bookings, and non-GAAP earnings per share, and ended the year with record product bookings of more than $1 billion,” stated Randall Lipps, Chairman, President, Chief Executive Officer, and founder of Omnicell. “We made tremendous progress advancing the autonomous pharmacy as we continued expanding our portfolio and investing in developing a single, cloud-based platform that can connect nearly all of our devices. The pandemic highlighted the need for increased digitization and virtualization of processes throughout the healthcare system, underscoring the strategic relevance of Omnicell’s solutions. Pharmacy
1

The following information was filed by Omnicell, Inc (OMCL) on Monday, February 1, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Omnicell, Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Omnicell, Inc.

Continue

Assess how Omnicell, Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Omnicell, Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account